表紙
市場調査レポート

バイオシミュレーションの世界市場予測 2020年:ソフトウェア・分子モデリング・PB/PK・PKPD・試験設計・毒性予測

Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 336606
出版日 ページ情報 英文 149 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
バイオシミュレーションの世界市場予測 2020年:ソフトウェア・分子モデリング・PB/PK・PKPD・試験設計・毒性予測 Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020
出版日: 2015年07月30日 ページ情報: 英文 149 Pages
概要

世界のバイオシミュレーション市場は、2015年の10億3,493万米ドルから、2020年までに21億799万米ドルへ、CAGR15.29%で拡大すると予測されています。2015年において、アプリケーション別では薬剤開発セグメントが最大のシェアを構成する見込みです。その他のアプリケーションセグメントは高い割合で成長すると予測されています。

当レポートでは、世界のバイオシミュレーション市場について調査し、市場の概要、主な促進因子、阻害因子、機会および課題について分析しており、アプリケーション・エンドユーザー・地域別の市場規模と収益予測、市場シェア予測、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 世界のバイオシミュレーション市場における有利な機会
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場区分
    • 製品別
    • アプリケーション別
    • エンドユーザー別
  • 市場ダイナミクス
    • 促進因子
    • 阻害因子
    • 機会
    • 課題
    • 動向

第6章 バイオシミュレーション市場:製品別

  • イントロダクション
  • ソフトウェア
  • サービス

第7章 バイオシミュレーション市場:アプリケーション別

  • イントロダクション
  • 薬剤開発
    • 前臨床試験
    • 臨床試験
  • 創薬
    • 標的特定・評価
    • LI (リード特定) ・LO (リード最適化)
  • その他のアプリケーション

第8章 バイオシミュレーション市場:エンドユーザー別

  • イントロダクション
  • 医薬品・バイオテクノロジー企業
  • 大学・政府研究機関
  • 開発業務受託機関
  • 規制団体
  • その他のエンドユーザー

第9章 世界のバイオシミュレーション市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他 (ROW)

第10章 競合情勢

  • イントロダクション
  • 戦略概要
  • バイオシミュレーション市場における主要企業
  • 競合状況・動向

第11章 企業プロファイル

  • イントロダクション
  • CERTARA USA, INC.
  • SIMULATION PLUS INC.
  • DASSAULT SYSTEMES SA
  • SCHRODINGER INC.
  • ADVANCED CHEMISTRY DEVELOPMENT, INC.
  • CHEMICAL COMPUTING GROUP, INC.
  • ENTELOS HOLDING CORPORATION
  • GENEDATA AG
  • PHYSIOMICS PLC
  • RHENOVIA PHARMA LTD.

第12章 付録

図表リスト

目次
Product Code: HIT 3629

The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development: Product portfolios of the top players in the biosimulation market.
  • Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOSIMULATION MARKET
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION (2015-2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY PRODUCT
    • 5.2.2. BY APPLICATION
    • 5.2.3. BY END USER
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Growth in the pharmaceutical and biotechnology industries
      • 5.3.1.2. Increase in R&D investments in the pharmaceutical and biotechnology industries
      • 5.3.1.3. Technological advancements
      • 5.3.1.4. Need to curtail drug discovery and development costs
      • 5.3.1.5. Growth in the biologics and biosimilars market and increased use of personalized medicines
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Lack of standardization
      • 5.3.2.2. Lack of trained professionals
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Emerging applications
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Limited knowledge of biological systems and processes
    • 5.3.5. TRENDS
      • 5.3.5.1. Collaborations of universities and research labs with suppliers

6. BIOSIMULATION MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. SOFTWARE
    • 6.2.1. PK/PD MODELING AND SIMULATION SOFTWARE
    • 6.2.2. MOLECULAR MODELING AND SIMULATION SOFTWARE
    • 6.2.3. PBPK MODELING AND SIMULATION SOFTWARE
    • 6.2.4. TOXICITY PREDICTION SOFTWARE
    • 6.2.5. TRIAL DESIGN SOFTWARE
    • 6.2.6. OTHER SOFTWARE
  • 6.3. SERVICES
    • 6.3.1. IN-HOUSE SERVICES
    • 6.3.2. EXTERNAL/CONTRACT SERVICES

7. BIOSIMULATION MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. DRUG DEVELOPMENT
    • 7.2.1. PRECLINICAL TESTING
      • 7.2.1.1. PK/PD
      • 7.2.1.2. ADME/Tox
    • 7.2.2. CLINICAL TRIALS
  • 7.3. DRUG DISCOVERY
    • 7.3.1. TARGET IDENTIFICATION AND VALIDATION
    • 7.3.2. LEAD IDENTIFICATION AND OPTIMIZATION
  • 7.4. OTHER APPLICATIONS

8. BIOSIMULATION MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 8.3. ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
  • 8.4. CONTRACT RESEARCH ORGANIZATIONS
  • 8.5. REGULATORY AUTHORITIES
  • 8.6. OTHER END USERS

9. GLOBAL BIOSIMULATION MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
  • 9.3. EUROPE
  • 9.4. ASIA
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. INTRODUCTION
  • 10.2. STRATEGIC OVERVIEW
  • 10.3. LEADING PLAYERS IN THE BIOSIMULATION MARKET
  • 10.4. COMPETITIVE SITUATION AND TRENDS
    • 10.4.1. PRODUCT UPGRADATION
    • 10.4.2. AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS
    • 10.4.3. NEW PRODUCT AND SERVICE LAUNCHES
    • 10.4.4. ACQUISITIONS
    • 10.4.5. OTHER DEVELOPMENTS

11. COMPANY PROFILES

  • 11.1. INTRODUCTION
  • 11.2. CERTARA USA, INC.
  • 11.3. SIMULATION PLUS INC.
  • 11.4. DASSAULT SYSTEMES SA
  • 11.5. SCHRODINGER INC.
  • 11.6. ADVANCED CHEMISTRY DEVELOPMENT, INC.
  • 11.7. CHEMICAL COMPUTING GROUP, INC.
  • 11.8. ENTELOS HOLDING CORPORATION
  • 11.9. GENEDATA AG
  • 11.10. PHYSIOMICS PLC
  • 11.11. RHENOVIA PHARMA LTD.

*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. OTHER DEVELOPMENTS
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: BIOSIMULATION MARKET SUMMARY
  • TABLE 2: GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES IS PROPELLING THE GROWTH OF THE BIOSIMULATION MARKET
  • TABLE 3: LACK OF STANDARDIZATION TO RESTRICT MARKET GROWTH
  • TABLE 4: EMERGING APPLICATIONS PRESENT SIGNIFICANT GROWTH OPPORTUNITIES FOR THE BIOSIMULATION MARKET
  • TABLE 5: LIMITED KNOWLEDGE OF BIOLOGICAL SYSTEMS AND PROCESSES POSE A CHALLENGE FOR THE BIOSIMULATION MARKET
  • TABLE 6: COLLABORATIONS OF UNIVERSITIES AND RESEARCH LABS WITH SUPPLIERS IS A MAJOR TREND OBSERVED IN THIS MARKET
  • TABLE 7: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 8: BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 9: BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 10: BIOSIMULATION MARKET SIZE FOR PK/PD MODELING AND SIMULATION SOFTWARE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 11: BIOSIMULATION MARKET SIZE FOR MOLECULAR MODELING AND SIMULATION SOFTWARE, BY REGION, 2013-2020 (USD MILLION
  • TABLE 12: BIOSIMULATION MARKET SIZE FOR PBPK MODELING AND SIMULATION SOFTWARE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 13: BIOSIMULATION MARKET SIZE FOR TOXICITY PREDICTION SOFTWARE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 14: BIOSIMULATION MARKET SIZE FOR TRIAL DESIGN SOFTWARE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 15: BIOSIMULATION MARKET SIZE FOR OTHER SOFTWARE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 16: BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 17: BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 18: BIOSIMULATION MARKET SIZE FOR IN-HOUSE SERVICES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 19: BIOSIMULATION MARKET SIZE FOR EXTERNAL/CONTRACT SERVICES , BY REGION, 2013-2020 (USD MILLION)
  • TABLE 20: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 21: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION, 2013-2020 (USD MILLION )
  • TABLE 22: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 23: BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION, 2013-2020 (USD MILLION )
  • TABLE 24: BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY REGION, 2013-2020 (USD MILLION )
  • TABLE 25: BIOSIMULATION MARKET SIZE FOR PK/PD, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 26: BIOSIMULATION MARKET SIZE FOR ADME/TOX, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 27: BIOSIMULATION MARKET SIZE FOR CLINICAL TRIALS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 28: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION, 2013-2020 (USD MILLION )
  • TABLE 29: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY REGION, 2013-2020 (USD MILLION )
  • TABLE 30: BIOSIMULATION MARKET SIZE FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 31: BIOSIMULATION MARKET SIZE FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 32: BIOSIMULATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2013-2020 (USD MILLION )
  • TABLE 33: BIOSIMULATION MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 34: BIOSIMULATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 35: BIOSIMULATION MARKET SIZE FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 36: BIOSIMULATION MARKET SIZE FOR CROS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 37: BIOSIMULATION MARKET SIZE FOR REGULATORY AUTHORITIES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 38: BIOSIMULATION MARKET SIZE FOR OTHER END USERS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 39: BIOSIMULATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 40: NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 46: NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 47: EUROPE: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 48: EUROPE: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013-2020 (USD MILLION)
  • TABLE 49: EUROPE: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 50: EUROPE: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 51: EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 52: EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 53: EUROPE: BIOSIMULATION MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 54: ASIA: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 55: ASIA: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013-2020 (USD MILLION)
  • TABLE 56: ASIA: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 57: ASIA: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 58: ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 59: ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 60: ASIA: BIOSIMULATION MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 61: ROW: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 62: ROW: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013-2020 (USD MILLION)
  • TABLE 63: ROW: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 64: ROW: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 65: ROW: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 66: ROW: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 67: ROW: BIOSIMULATION MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 68: RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2015
  • TABLE 69: MARKET DEVELOPMENTS BETWEEN 2013-2015
  • TABLE 70: PRODUCT UPGRADATION, 2013-2015
  • TABLE 71: AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS, 2013-2015
  • TABLE 72: NEW PRODUCT AND SERVICE LAUNCHES, 2013-2015
  • TABLE 73: ACQUISITIONS, 2013-2015
  • TABLE 74: OTHER DEVELOPMENTS, 2013-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL BIOSIMULATION MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2015 VS. 2020 (USD MILLION)
  • FIGURE 8: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 9: BIOSIMULATION MARKET SIZE, BY END USER, 2015 VS. 2020 (USD MILLION)
  • FIGURE 10: BIOSIMULATION MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 11: GLOBAL BIOSIMULATION MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: SOFTWARE PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015
  • FIGURE 13: EUROPE TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 14: EUROPEAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 15: BIOSIMULATION MARKET SEGMENTATION: BY PRODUCT
  • FIGURE 16: BIOSIMULATION MARKET SEGMENTATION: BY APPLICATION
  • FIGURE 17: BIOSIMULATION MARKET SEGMENTATION: BY END USER
  • FIGURE 18: GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES WILL DRIVE THE BIOSIMULATION MARKET
  • FIGURE 19: NEW PHARMACEUTICAL DRUG LAUNCHES (2003-2013)
  • FIGURE 20: BIOSIMULATION MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 21: BIOSIMULATION MARKET, BY PRODUCT, 2015 (USD MILLION)
  • FIGURE 22: BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 23: BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 24: BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • FIGURE 25: BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • FIGURE 26: BIOSIMULATION MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 27: DRUG DEVELOPMENT SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN 2015
  • FIGURE 28: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION, 2015 VS. 2020 (USD MILLION )
  • FIGURE 29: NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR DRUG DEVELOPMENT APPLICATIONS
  • FIGURE 30: BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 31: NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR PRECLINICAL TESTING APPLICATIONS
  • FIGURE 32: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION, 2015 VS. 2020 (USD MILLION )
  • FIGURE 33: EUROPE IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DRUG DISCOVERY APPLICATIONS
  • FIGURE 34: OTHER APPLICATIONS MARKET IN EUROPE TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 35: BIOSIMULATION MARKET, BY END USER
  • FIGURE 36: BIOSIMULATION MARKET SIZE, BY END USER, 2015 (USD MILLION)
  • FIGURE 37: NUMBER OF BIOTECHNOLOGY AND PHARMACEUTICAL PATENTS GRANTED IN 2012, BY REGION
  • FIGURE 38: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT TO WITNESS HIGHEST GROWTH IN EUROPE
  • FIGURE 39: PUBLIC-SECTOR RESEARCH FUNDING DRIVING THE GROWTH OF THE ACADEMIC & GOVERNMENT RESEARCH INSTITUTES END-USER SEGMENT
  • FIGURE 40: NORTH AMERICA DOMINATES MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
  • FIGURE 41: NORTH AMERICA EXPECTED TO DOMINATE BIOSIMULATION MARKET FOR CROS
  • FIGURE 42: EUROPE IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES
  • FIGURE 43: EUROPE TO WITNESS HIGHEST GROWTH IN THE BIOSIMULATION MARKET FOR OTHER END USERS IN THE FORECAST PERIOD
  • FIGURE 44: BIOSIMULATION MARKET SEGMENTATION, BY REGION
  • FIGURE 45: NORTH AMERICA TO DOMINATE THE GLOBAL BIOSIMULATION MARKET IN THE FORECAST PERIOD
  • FIGURE 46: BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH FROM 2015 TO 2020
  • FIGURE 47: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 48: BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN NORTH AMERICA IN 2015
  • FIGURE 49: DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN NORTH AMERICA BY 2020
  • FIGURE 50: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO FORM THE LARGEST END-USER SEGMENT IN NORTH AMERICA IN 2015
  • FIGURE 51: EUROPE: MARKET SNAPSHOT
  • FIGURE 52: BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE EUROPEAN BIOSIMULATION MARKET IN 2015
  • FIGURE 53: DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN EUROPE BY 2020
  • FIGURE 54: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN EUROPE IN 2015
  • FIGURE 55: BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN ASIA IN 2015
  • FIGURE 56: DRUG DEVELOPMENT APPLICATION SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN ASIA BY 2020
  • FIGURE 57: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN ASIA IN 2015
  • FIGURE 58: BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE ROW BIOSIMULATION MARKET IN 2015
  • FIGURE 59: DRUG DEVELOPMENT APPLICATION SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN THE ROW REGION BY 2020
  • FIGURE 60: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT TO DOMINATE THE ROW MARKET FOR BIOSIMULATION IN 2015
  • FIGURE 61: KEY DEVELOPMENTS IN THE BIOSIMULATION MARKET, 2013-2015
  • FIGURE 62: GEOGRAPHICAL MIX OF THE TOP 4 MARKET PLAYERS
  • FIGURE 63: COMPANY SNAPSHOT: SIMULATION PLUS INC.
  • FIGURE 64: COMPANY SNAPSHOT: DASSAULT SYSTEMES SA
  • FIGURE 65: COMPANY SNAPSHOT: PHYSIOMICS PLC
Back to Top